Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer

European Urology

Volumn 58, Issue 3, 2010, Pages 433-441

  Van Rhijn, Bas W G ^a,b,c   Zuiverloon, Tahlita C M ^a,d   Vis, André N ^a,b   Radvanyi, Franois ^e   Van Leenders, Geert J L H ^d   Ooms, Bert C M ^f   Kirkels, Wim J ^a   Lockwood, Gina A ^c   Boevé, Egbert R ^b   Jöbsis, Adriaan C ^b   Zwarthoff, Ellen C ^d   Van Der Kwast, Theo H ^c,d  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b SINT FRANCISCUS GASTHUIS   (Netherlands)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

^e INSTITUT CURIE   (France)

^f University Health Network ^*  (Netherlands)

Author keywords

Bladder cancer; EORTC; FGFR3; Grade; MIB 1; Molecular marker; Observer variability; Progression; Recurrence; Survival

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 3; MOLECULAR MARKER; MONOCLONAL ANTIBODY KI 67;

ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER GROWTH; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CLINICAL ASSESSMENT; DISEASE FREE INTERVAL; DISEASE FREE SURVIVAL; EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON MUSCLE INVASIVE BLADDER CANCER; PREDICTIVE VALIDITY; PRIORITY JOURNAL; REPRODUCIBILITY; SCORING SYSTEM;

AGED; FEMALE; HUMANS; MALE; NEOPLASM INVASIVENESS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; URINARY BLADDER NEOPLASMS;

EID: 77955508884     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2010.05.043     Document Type: Article

References (23)

1. B.W. van Rhijn, A.N. Vis, and T.H. van der Kwast Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome J Clin Oncol 21 2003 1912 1921
2. R.J. Sylvester, A.P.M. van der Meijden, and W. Oosterlinck Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials Eur Urol 49 2006 466 477
3. M. Babjuk, W. Oosterlinck, R. Sylvester, E. Kaasinen, A. Böhle, and J. Palou-Redorta EAU Guidelines on non-muscle-invasive urothelial carcinoma of the bladder Eur Urol 54 2008 303 314
4. B.W.G. van Rhijn, M. Burger, and Y. Lotan Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy Eur Urol 56 2009 430 442
5. Z. Kirkali, T. Chan, and M. Manoharan Bladder cancer: epidemiology, staging and grading, and diagnosis Urology 66 Suppl 6A 2005 4 34
6. F.K. Mostofi, L.H. Sobin, and H. Torloni Histological typing of urinary bladder tumours International Classification of Tumours, No. 10 Geneva, Switzerland: World Health Organization 1973 p. 21-31
7. D.H. Sobin, C.H. Wittekind, TNM Classification of Malignant Tumours ed 6 2002 Wiley-Liss New York 199 202
8. B.J. Schmitz-Dräger, P.J. Goebell, T. Ebert, and Y. Fradet p53 immunohistochemistry as a prognostic marker in bladder cancer: playground for urology scientists? Eur Urol 38 2000 691 700
9. C. Billerey, D. Chopin, and M.-H. Aubriot-Lorton Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors Am J Pathol 158 2001 1955 1959
10. S.F. Shariat, R. Ashfaq, A.I. Sagalowsky, and Y. Lotan Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma J Urol 177 2007 481 487
11. J. Eble, G. Sauter, J. Epstein, and I. Sesterhenn Pathology and genetics of tumours of the urinary system and male genital organs 2004 IARC Press Lyon, France
12. J.M. van Oers, I. Lurkin, and A.J. van Exsel A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine Clin Cancer Res 11 2005 7743 7748
13. M. Burger, M.N.M. van der Aa, and J.M.M. van Oers Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study Eur Urol 54 2008 835 844
14. W. Otto, S. Denzinger, and S. Bertz No mutations of FGFR3 in normal urothelium in the vicinity of urothelial carcinoma of the bladder harbouring activating FGFR3 mutations in patients with bladder cancer Int J Cancer 125 2009 2205 2208
15. V. Margulis, Y. Lotan, and P.I. Karakiewicz Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer J Natl Cancer Inst 101 2009 114 119
16. B.W.G. van Rhijn, G.J.L.H. van Leenders, and E.C.M. Ooms The pathologist's mean grade is constant and individualizes the prognostic value of bladder cancer grading Eur Urol 57 2010 1052 1057
17. K. Zieger, L. Dyrskjøt, and C. Wiuf Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors Clin Cancer Res 11 2005 7709 7719
18. B.W. van Rhijn, I. Lurkin, and D.K. Chopin Combined microsatellite and FGFR3 mutation analysis enables a highly sensitive detection of urothelial cell carcinoma in voided urine Clin Cancer Res 9 2003 257 263
19. A. Lamy, F. Gobet, and M. Laurent Molecular profiling of bladder tumors based on the detection of FGFR3 and TP53 mutations J Urol 176 2006 2686 2689
20. S. Hernández, E. López-Knowles, and J. Lloreta Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas J Clin Oncol 24 2006 3664 3671
21. D.C. Tomlinson, O. Baldo, P. Harnden, and M.A. Knowles FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer J Pathol 213 2007 91 98
22. K. Junker, J.M. van Oers, E.C. Zwarthoff, I. Kania, J. Schubert, and A. Hartmann Fibroblast growth factor receptor 3 mutations in bladder tumors correlate with low frequency of chromosome alterations Neoplasia 10 2008 1 7
23. G.T. MacLennan, Z. Kirkali, and L. Cheng Histologic grading of noninvasive papillary urothelial neoplasms Eur Urol 51 2007 889 898